Drugging the epigenome in the age of precision medicine
Abstract Background Modulating the epigenome has long been considered a potential opportunity for therapeutic intervention in numerous disease areas with several approved therapies marketed, primarily for cancer. Despite the overall promise of early approaches, however, these drugs have been plagued...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | Clinical Epigenetics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13148-022-01419-z |
| _version_ | 1797952516464312320 |
|---|---|
| author | Taylor Feehley Charles W. O’Donnell John Mendlein Mahesh Karande Thomas McCauley |
| author_facet | Taylor Feehley Charles W. O’Donnell John Mendlein Mahesh Karande Thomas McCauley |
| author_sort | Taylor Feehley |
| collection | DOAJ |
| description | Abstract Background Modulating the epigenome has long been considered a potential opportunity for therapeutic intervention in numerous disease areas with several approved therapies marketed, primarily for cancer. Despite the overall promise of early approaches, however, these drugs have been plagued by poor pharmacokinetic and safety/tolerability profiles due in large part to off-target effects and a lack of specificity. Results Recently, there has been marked progress in the field on a new generation of epigenomic therapies which address these challenges directly by targeting defined loci with highly precise, durable, and tunable approaches. Here, we review the promise and pitfalls of epigenetic drug development to date and provide an outlook on recent advances and their promise for future therapeutic applications. Conclusions Novel therapeutic modalities leveraging epigenetics and epigenomics with increased precision are well positioned to advance the field and treat patients across disease areas in the coming years. |
| first_indexed | 2024-04-10T22:47:37Z |
| format | Article |
| id | doaj.art-dd268b606a184aa3bc3d159dafc08f24 |
| institution | Directory Open Access Journal |
| issn | 1868-7083 |
| language | English |
| last_indexed | 2024-04-10T22:47:37Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Clinical Epigenetics |
| spelling | doaj.art-dd268b606a184aa3bc3d159dafc08f242023-01-15T12:14:54ZengBMCClinical Epigenetics1868-70832023-01-0115111310.1186/s13148-022-01419-zDrugging the epigenome in the age of precision medicineTaylor Feehley0Charles W. O’Donnell1John Mendlein2Mahesh Karande3Thomas McCauley4Omega TherapeuticsOmega TherapeuticsFlagship PioneeringOmega TherapeuticsOmega TherapeuticsAbstract Background Modulating the epigenome has long been considered a potential opportunity for therapeutic intervention in numerous disease areas with several approved therapies marketed, primarily for cancer. Despite the overall promise of early approaches, however, these drugs have been plagued by poor pharmacokinetic and safety/tolerability profiles due in large part to off-target effects and a lack of specificity. Results Recently, there has been marked progress in the field on a new generation of epigenomic therapies which address these challenges directly by targeting defined loci with highly precise, durable, and tunable approaches. Here, we review the promise and pitfalls of epigenetic drug development to date and provide an outlook on recent advances and their promise for future therapeutic applications. Conclusions Novel therapeutic modalities leveraging epigenetics and epigenomics with increased precision are well positioned to advance the field and treat patients across disease areas in the coming years.https://doi.org/10.1186/s13148-022-01419-zEpigeneticsEpigenomicsPrecisionSpecificityTherapeutics |
| spellingShingle | Taylor Feehley Charles W. O’Donnell John Mendlein Mahesh Karande Thomas McCauley Drugging the epigenome in the age of precision medicine Clinical Epigenetics Epigenetics Epigenomics Precision Specificity Therapeutics |
| title | Drugging the epigenome in the age of precision medicine |
| title_full | Drugging the epigenome in the age of precision medicine |
| title_fullStr | Drugging the epigenome in the age of precision medicine |
| title_full_unstemmed | Drugging the epigenome in the age of precision medicine |
| title_short | Drugging the epigenome in the age of precision medicine |
| title_sort | drugging the epigenome in the age of precision medicine |
| topic | Epigenetics Epigenomics Precision Specificity Therapeutics |
| url | https://doi.org/10.1186/s13148-022-01419-z |
| work_keys_str_mv | AT taylorfeehley druggingtheepigenomeintheageofprecisionmedicine AT charleswodonnell druggingtheepigenomeintheageofprecisionmedicine AT johnmendlein druggingtheepigenomeintheageofprecisionmedicine AT maheshkarande druggingtheepigenomeintheageofprecisionmedicine AT thomasmccauley druggingtheepigenomeintheageofprecisionmedicine |